. "Mich\u00E1lek, J." . "Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients" . "RIV/00843989:_____/05:00100053" . "0340-6199" . "000232695900005" . . "11" . . . . "Dlouhodob\u00E9 pravideln\u00E9 echokardiografick\u00E9 vy\u0161et\u0159en\u00ED pozdn\u00ED antracyklinov\u00E9 toxicity a jeho prevence dexrazonem u d\u011Btsk\u00FDch pacient\u016F"@cs . "DE - Spolkov\u00E1 republika N\u011Bmecko" . "Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients"@en . "The authors conducted an 8-year prospective non-randomised study to determine whether dexrazoxane (ICRF-187) would reduce late anthracycline-induced cardiotoxicity in patients treated in childhood for haematological malignancy. The authors examined prospectively 75 patients (40 male/35 female) aged 2-17 years (median 6.5 years) at the time of diagnosis. The cardioprotection was given to 53 patients (26 male/17 female) and the standard protocol was used in 22 patients (14 male/8 female). The prospective echocardiographic evaluation was done before and after the chemotherapy and every year during the follow-up period. Dynamic stress echocardiography (DSE) was assessed in the final year. The clinical cardiotoxicity was not diagnosed. Higher cumulative doses of anthracycline were given in the dexrazoxane group (234+/-58 mg/m(2), median 240 mg/m(2) versus 203+/-86 mg/m(2), median 210 mg/m(2), P <0.04) and a significantly higher percentage of patients received cumulative doses >240 mg/m(2) o" . . "anthracycline; cardiotoxicity; children; dexrazoxane"@en . . "Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients"@en . "Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients" . "7"^^ . "[86A52F5AB57F]" . . "528420" . . "Dlouhodob\u00E9 pravideln\u00E9 echokardiografick\u00E9 vy\u0161et\u0159en\u00ED pozdn\u00ED antracyklinov\u00E9 toxicity a jeho prevence dexrazonem u d\u011Btsk\u00FDch pacient\u016F"@cs . "1"^^ . . "164" . "Auto\u0159i p\u0159edkl\u00E1daj\u00ED 8 let\u00E9 zku\u0161enosti nerandomizovan\u00E9 studie zkoumaj\u00EDc\u00ED zda dexrazoxane (ICRF-187) m\u016F\u017Ee sn\u00ED\u017Eit anthracyklinem indukovanou kardiotoxicitu u pacient\u016F l\u00E9\u010Den\u00FDch v d\u011Btstv\u00ED pro hematologickou malignitu. Auto\u0159i prospektivn\u011B vy\u0161et\u0159ili soubor 75 pacient\u016F (40mu\u017E\u016F/35 \u017Een) ve v\u011Bku 2-17 let ( median 67,5 let) v dob\u011B prezentace diagnozy. Kardioprotekce byla pod\u00E1na 53 pacient\u016Fm (26mu\u017E\u016Fm/17 \u017Een\u00E1m) a standardn\u00ED protokol byl pou\u017Eit u 22 pacient\u016F (14 mu\u017E\u016F/8 \u017Een\u00E1m) Prospektivn\u00ED echokardiografick\u00E9 vy\u0161et\u0159en\u00ED bylo provedeno p\u0159ed a po chemoterapii a n\u00E1sledn\u011B ka\u017Ed\u00FD rok sledovac\u00EDho obdob\u00ED.Dynamick\u00E1 stress echokardiografie byla provedena v posledn\u00EDm roce.Vy\u0161\u0161\u00ED kumulativn\u00ED d\u00E1vky anthracyklinu byly pod\u00E1ny v dexrazonov\u00E9 skupin\u011B (234+58mg/m2, median 240mg/m2, versus 203+86mg/m2, median 210mg/m2, P < 0.04) a signifikantn\u011B vy\u0161\u0161\u00ED procento pacient\u016F obdr\u017Eelo kumulativn\u00ED d\u00E1vku >240mg/m2 anthracyclinu ( P<0.05). B\u011Bhem sledov\u00E1n\u00ED frakcionovan\u00E9 zkr\u00E1cen\u00ED (FS) pokleslo ve skupin\u011B bez bez dexrazoxanu jen"@cs . . . "Elbl, L." . . "The authors conducted an 8-year prospective non-randomised study to determine whether dexrazoxane (ICRF-187) would reduce late anthracycline-induced cardiotoxicity in patients treated in childhood for haematological malignancy. The authors examined prospectively 75 patients (40 male/35 female) aged 2-17 years (median 6.5 years) at the time of diagnosis. The cardioprotection was given to 53 patients (26 male/17 female) and the standard protocol was used in 22 patients (14 male/8 female). The prospective echocardiographic evaluation was done before and after the chemotherapy and every year during the follow-up period. Dynamic stress echocardiography (DSE) was assessed in the final year. The clinical cardiotoxicity was not diagnosed. Higher cumulative doses of anthracycline were given in the dexrazoxane group (234+/-58 mg/m(2), median 240 mg/m(2) versus 203+/-86 mg/m(2), median 210 mg/m(2), P <0.04) and a significantly higher percentage of patients received cumulative doses >240 mg/m(2) o"@en . . "Hrstkov\u00E1, H." . "P(NR8006), Z(MSM0021622402)" . "Bla\u017Eek, Bohum\u00EDr" . "5"^^ . "Tom\u00E1\u0161kov\u00E1, I." . . . . "RIV/00843989:_____/05:00100053!RIV09-MSM-00843989" . "European journal of pediatrics" . .